After decades of determined research, RNAi drugs have their day in the sun
A panel at Biotech Showcase last week provided an outlook for a new class of drugs that only entered the market two years ago, but was decades in the making.
For CAR-Ts to be successful, figuring out manufacturing is key
Efficacy, safety and reimbursement are all important things for CAR-T makers to figure out, but manufacturing is no less important.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Cell, gene therapies demand creative payment models, but implementing them is a challenge, CEOs say
Performance- and time-based payment models - like the one bluebird bio has proposed for LentiGlobin - are especially harder to put into practice in the US than in Europe, some executives said at this week's JPM conference.
Industry execs forecast the year ahead for gene therapy at Biotech Showcase
Hospitals - especially in Europe - anticipate growing interest from international patients. But a wave of industry consolidation is debatable.
Five of Biotech Showcase’s most interesting startups
The startups highlighted stood out from the pack of some 300 life sciences companies presenting at this week's Biotech Showcase.